Company (Symbol)

University/Non-Profit [Scientist]

Type of Agreement

Product Area

Details (Month)

Affymetrix Inc. (AFFX)

University of Wisconsin, University of Colorado, the Canadian Genetic Diseases Network and the H. Lee Moffitt Cancer

Academic access agreement

Affymetrix's GeneChip technology

Affymetrix announced the addition of the four listed entities to its list of AcademicAccess customers; the agreements with each include standard terms and conditions and volume pricing provisions that allow researchers at these facilities broad access to GeneChip technology; further details ND (11/99)

Ambrx Inc.*

Johns Hopkins University [Dr. Randall Reed, Dr. Solomon Snyder, Dr. King-Wai Yu]

Technology access agreement

Enabling technology and molecules related to chemosensation and olfaction

Ambrx signed an exclusive agreement with Hopkins whereby the company will have access to certain key chemosensory proteins and methods from the laboratories of Reed, Snyder and Yu; further details ND (10/99)

Rockefeller University [Dr. Peter Mombaerts]

License and research agreement

Molecules related to olfaction

Ambrx signed an exclusive license and research agreement with Rockefeller University whereby the company will have access to receptors involved in human olfaction for the purpose of building its chemosensory platform; further details ND (10/99)

Harvard University [Dr. Linda Buck, Dr. Catherine Dulac]

Option agreement

Chemosensory receptors

Ambrx signed an exclusive option agreement with Harvard regarding a family of chemosensory receptors Buck and Dulac; the technology includes the DNA sequences and related proteins of a large multigene family encoding novel mammalian pheromone receptors; further details ND (10/99)

American Biogenetic Sciences

Chinese Academy of Medical Sciences and the Institute of Medicinal Plant Development (IMPLAD)

Marketing agreement

Traditional Chinese herbal medicines

American Biogenetics (ABS) and the academy entered an agreement in which ABS will market and sell traditional Inc.(MABXA) Chinese medicines worldwide; ABS will have the opportunity to select herbal products and components from IMPLAD's array of products; ABS or its licensees will be permitted to use the academy's seal indicating quality compliance for all medicines produced under the agreement; further details ND (7/99)

Atairgin Technologies Inc.*

Washington State University

Research agreement

Fertility and cancer therapeutics

Atairgin announced an extensive research collaboration with Washington State to further advance its platform technology to additional therapeutic applications; further details ND (9/99)

Aurora Biosciences Corp. (ABSC)

National Cancer Institute

Research agreement

Aurora's GenomeScreen technology

Aurora and the National Cancer Institute (NCI) entered a collaboration to use Aurora's GenomeScreen technology to identify rare or low abundance transcripts in tumor cells (7/99)

Cel-Sci Corp. (AMEX:HIV)

Johns Hopkins University [Dr. Noel Rose]

Collaboration agreement

Cel-Sci's immune system technology

Cel-Sci and Hopkins entered a collaborative study using Cel-Sci's ligand epitope antigen presentation system (LEAPS) and antigen directed apoptosis (AdapT) technologies for the treatment of autoimmune myocarditis (11/99)

Chiron Corp. (CHIR)

Norwegian Institutes of Public Health (NIPH)

Development agreement

Combination vaccine against Neisseria meningitidis

Chiron and NIPH entered a development agreement for a combination vaccine using Chiron's conjugate vaccine against meningococcal B disease, and NIPH's vaccine against meningococcal B; Chiron will market the new combination vaccine, as well as NIPH's vaccine in countries outside of Norway (11/99)

Genomica Corp.*

University of Oxford (UK)

License agreement

Genomica's Discovery Manager pharmacogenomic software

Genomica licensed its software to the University of Oxford to facilitate its genome screening program; terms of the agreement ND (8/99)

Wellcome Trust Centre for Human Genetics

License agreement

Genomica's Discovery Manager pharmacogenomic software

Genomica licensed its software to the Wellcome Trust Centre for genetic analysis in support of bioinformatics within the centre; terms of the agreement ND (8/99)

Genset SA (France; NM: GENSET; GENXY)

Commissariat a l'Energie

Development Atomique (CEA)

Genotyping technology agreement

Genset and the CEA entered a collaboration for the development of a large-capacity genotyping microprocessor; the agreement provides that Genset and the CEA will each be able to use the results of their collaboration program in their internal research programs; the two parties will cooperate to commercialize the results, either through a joint venture or with other partners; in the event the parties use the results independently, Genset will have commercial exclusivity in the field of genotyping, other fields being open to commercialization by the CEA (11/99)

ImmunoGen Inc. (IMGN)

Duke University and Johns Hopkins University

License agreement

ImmunoGen's TumorActivated Prodrug (TAP) technology

ImmunoGen purchased an option from Duke and Hopkins to license a novel, cancer-targeting antibody, developed by investigators at the two institutions, for exclusive use with its TAP technology; terms ND (11/99)

Incyte Pharmaceuticals Inc. (INCY)

University of Washington

Research agreement

DNA sequencing

Incyte and the University of Washington entered a collaboration in which Incyte will perform DNA sequencing and provide data to the university; the University of Washington Genome Center will refine the data and deposit it, at varous stages, into Genbank, the publicly accessible collection of data from the Human Genome Project (11/99)

Inhibitex Inc.*

Red Cross Foundation Central Laboratory (ZLB, a foundation of the Swiss Red Cross)

Collaboration agreement

Antibody-based products to treat antibiotic-resistant S. aureus infections

Inhibitex and ZLB entered an agreement to collaborate on the development of antibody-based products to treat and prevent antibiotic-resistant S. aureus infections; Inhibitex will receive an up-front cash payment and funding to cover research and development of its antibody-based technology; upon achieving specific preclinical development milestones, Inhibitex and ZLB will negotiate an agreement to commercialize products based on both monoclonal and polyclonal antibodies; if the program and the agreement expand, ZLB will obtain worldwide manufacturing rights and marketing rights for Europe and the Middle East, as well as rights covering polyclonal antibody-based products in Asia; in exchange for these rights and upon completion of the agreement, Inhibitex will receive additional cash payments, as well as further research support and royalties on sales; Inhibitex will also retain marketing rights to the antibody-based technologies in North America and all other areas, excluding those specifically assigned to ZLB (11/99)

LifeCell Corp. (LIFC)

University of Texas M.D. Anderson Cancer Center and Pharmacia & Upjohn (P&U)

Collaborative study agreement

LifeCell's Thrombosol

LifeCell, M.D. Anderson and P&U initiated a study of ThromboSol focusing on safety and clinical efficacy; terms of the agreement ND (7/99)

LigoCyte Pharmaceuticals*

Department of Defense

Research agreement

Biodefense technology

LigoCyte will receive $1.5M in federal funding for research of biodefense measures that seek to identify and prepare to deal with infectious agents and their toxins in the environment, including E. coli, the Norwalk virus and brucellosis (10/99)

Neurologic Inc.*

National Institutes of Health (NIH)

License agreement

Diagnostic test for Alzheimer's disease

NeuroLogic acquired an exclusive worldwide license from NIH for a diagnostic test for Alzheimer's; NeuroLogic will also own rights to the technology underlying the test; terms of the agreement ND (9/99)

Quark Biotech Inc.*

New York Blood Center

Research and [Jan Visser, PhD]

Stem cell research license agreement

Quark and the New York Blood Center (NYBC) signed a collaborative research and licensing agreement to identify genes implicated in hemopoietic stem cell differentiation; Quark will gain access to various purified stem cell subpopulations provided by Visser; Quark will apply its gene discovery technology platform to the stem cells to identify genes and proteins that are expressed during the stem cell differentiation process; terms of the agreement ND (8/99)

Repligen Corp. (RGEN)

National Cancer Institute

Clinical trial agreement

Repligen's CTLA4-Ig compound for selective immune response inhibition

Repligen and NCI entered a clinical trial agreement for a Phase II trial of CTLA4-Ig, evaluating the compound's ability to prevent the development of graft-vs.-host disease in patients undergoing unmatched donor bone marrow transplants; NCI will submit an IND for the drug and sponsor the trial; Repligen will provide the CTLA4-Ig and will support laboratory measurements designed to confirm the drug's effect and the specificity of the induced immune tolerance (9/99)

SciClone Pharmaceuticals (SCLN)

National Institutes of Health (NIH)

License agreement

DAX protein repair therapy for cystic fibrosis

SciClone acquired the rights to DAX from NIH; the company plans to pursue fast-track and orphan drug designation from the FDA, and development grants; terms of the acquisition ND (10/99)

StressGen Biotechnologies Corp. (TSE:SSB)

National Cancer Institute

Clinical trial agreement

StressGen's HspE7 for the treatment of human papillomavirus (HPV)

StressGen and NCI entered a clinical trial agreement for the co-development of HspE7; NCI's division of cancer treatment and diagnosis will work collaboratively with StressGen to develop a general plan for clinical development of the drug, and then solicit clinical research protocols from independent investigators and cooperative research groups affiliated with NCI (11/99)

SuperGen Inc. (SUPG)

Stehlin Foundation for Cancer Research

Research agreement

Anticancer compounds

SuperGen and Stehlin extended their 1997 research agreement whereby SuperGen acquired global rights to other camptothecins and additional anticancer compounds; in addition, reductions will be made with respect to SuperGen's royalty payments for sales of rubitecan above $500M (11/99)

Third Wave Technologies

University of Guelph (Canada) and Health Canada

Research and license agreement

Third Wave's Invader technology

Third Wave, University of Guelph and Health Canada entered a research and license agreement for the detection and typing of verocytotoxin-producing E. coli; Guelph and Health Canada will have access to Third Wave's technologies for developing assays; Third Wave has an option to obtain exclusive worldwide commercial rights to the developed technology; the agreement includes other terms and conditions designed to promote academic researchers' freedom to collaborate and publish scientific results (10/99)

VaxGen Inc. (VXGN)

Centers for Disease Control and Prevention (CDC)

Clinical trial

HIV vaccine agreement

The CDC will contribute funds to support additional research at five of the 56 clinics in the U.S. currently conducting Phase III trials of VaxGen's AIDSvax vaccine; the CDC will contribute $2M annually, for four years, to the clinics (10/99)

VitaResc Biotech AG

Scottish National Blood Transfusion Service (Germany)

License agreement

Anti-lipopolysaccharide drug for the treatment of systemic inflammatory response (SIRS)

VitaResc received exclusive worldwide rights from the Scottish National Blood Transfusion Service (SNBTS) to develop an anti-lipopolysaccharide drug resulting from a joint research effort between SNBTS and Novartis; Novartis has retained a first right of negotiation to re-enter into the development of the antibody when certain milestones have been achieved by VitaResc (10/99)

Xanthon Inc.*

North Carolina State University, Raleigh (NCSU)

Research agreement

Electron transfer reactions

Xanthon entered into a sponsored research agreement with NCSU for the characterization of electron transfer reactions at indium/tin oxide electrode interfaces; the project is intended to provide information relative to the Xanthon Xpression analysis system (10/99)

Notes:

Unless otherwise noted, the stock symbols listed are on the Nasdaq market.

* Privately held company

ND = Not disclosed.